Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China · Delayed Price · Currency is CNY 11.33
+0.07 (0.62%)
Feb 4, 2026, 3:04 PM CST
SHE:301060 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,524 | 1,742 | 1,668 | 4,182 | 1,766 | 1,231 |
Other Revenue | 0.25 | 0.25 | 6.72 | 17.5 | 11.91 | 6.83 |
| 1,524 | 1,742 | 1,674 | 4,199 | 1,778 | 1,238 | |
Revenue Growth (YoY) | -11.61% | 4.05% | -60.13% | 136.14% | 43.62% | 7.34% |
Cost of Revenue | 1,202 | 1,410 | 1,345 | 2,420 | 1,105 | 842.97 |
Gross Profit | 321.94 | 332.53 | 329.31 | 1,779 | 672.9 | 395.22 |
Selling, General & Admin | 289.45 | 304.25 | 302.06 | 539.66 | 319.11 | 199.2 |
Research & Development | 53.41 | 59.97 | 48.86 | 109.4 | 39.44 | 21.8 |
Other Operating Expenses | 14.31 | 5.01 | 3.27 | 3.5 | 4.93 | 4.55 |
Operating Expenses | 365.57 | 394.9 | 484.87 | 708.33 | 378.75 | 237.04 |
Operating Income | -43.62 | -62.37 | -155.55 | 1,071 | 294.15 | 158.18 |
Interest Expense | -7.6 | -10.81 | -8.17 | -8.46 | -3.27 | - |
Interest & Investment Income | 5.11 | 10.63 | 5.58 | 3.53 | 8.93 | 8.15 |
Currency Exchange Gain (Loss) | -1.02 | -1.02 | -0.57 | -0.56 | 0.02 | -0.24 |
Other Non Operating Income (Expenses) | 5.87 | 1.52 | 0.99 | -0.05 | -0.21 | -5.39 |
EBT Excluding Unusual Items | -41.27 | -62.06 | -157.72 | 1,065 | 299.62 | 160.69 |
Impairment of Goodwill | - | - | -9.97 | -12.45 | - | - |
Gain (Loss) on Sale of Investments | -13.77 | -13.06 | -2.12 | 1.66 | 3.93 | 0.53 |
Gain (Loss) on Sale of Assets | 5.35 | 5.67 | 1.93 | -0.36 | -0.03 | 0.31 |
Asset Writedown | 47.8 | -17.14 | -1.26 | -115.07 | - | - |
Legal Settlements | -19.93 | -19.93 | -5.09 | - | - | - |
Other Unusual Items | 5.13 | 3.71 | 20.99 | -34.79 | 14.51 | 0.78 |
Pretax Income | -16.69 | -102.82 | -153.24 | 904.44 | 318.03 | 162.31 |
Income Tax Expense | 18.51 | -4.23 | 8.47 | 165.39 | 56.41 | 27.83 |
Earnings From Continuing Operations | -35.2 | -98.59 | -161.71 | 739.06 | 261.62 | 134.48 |
Minority Interest in Earnings | -34.32 | -10.85 | 20.12 | -121.73 | -57.78 | -24.1 |
Net Income | -69.52 | -109.44 | -141.59 | 617.32 | 203.84 | 110.38 |
Net Income to Common | -69.52 | -109.44 | -141.59 | 617.32 | 203.84 | 110.38 |
Net Income Growth | - | - | - | 202.85% | 84.68% | 19.66% |
Shares Outstanding (Basic) | 403 | 405 | 405 | 401 | 352 | 352 |
Shares Outstanding (Diluted) | 403 | 405 | 405 | 401 | 352 | 352 |
Shares Change (YoY) | 0.51% | 0.19% | 1.00% | 13.63% | 0.02% | -0.02% |
EPS (Basic) | -0.17 | -0.27 | -0.35 | 1.54 | 0.58 | 0.31 |
EPS (Diluted) | -0.17 | -0.27 | -0.35 | 1.54 | 0.58 | 0.31 |
EPS Growth | - | - | - | 166.52% | 84.64% | 19.68% |
Free Cash Flow | 355.38 | 139.7 | 148.1 | -145.91 | 104.63 | 123.33 |
Free Cash Flow Per Share | 0.88 | 0.34 | 0.37 | -0.36 | 0.30 | 0.35 |
Dividend Per Share | 0.200 | 0.200 | - | 0.300 | 0.300 | - |
Gross Margin | 21.12% | 19.09% | 19.67% | 42.37% | 37.84% | 31.92% |
Operating Margin | -2.86% | -3.58% | -9.29% | 25.50% | 16.54% | 12.78% |
Profit Margin | -4.56% | -6.28% | -8.46% | 14.70% | 11.46% | 8.91% |
Free Cash Flow Margin | 23.32% | 8.02% | 8.85% | -3.48% | 5.88% | 9.96% |
EBITDA | 23.83 | -2.73 | -106.34 | 1,133 | 338.96 | 201.87 |
EBITDA Margin | 1.56% | -0.16% | -6.35% | 26.98% | 19.06% | 16.30% |
D&A For EBITDA | 67.46 | 59.64 | 49.21 | 62.21 | 44.82 | 43.69 |
EBIT | -43.62 | -62.37 | -155.55 | 1,071 | 294.15 | 158.18 |
EBIT Margin | -2.86% | -3.58% | -9.29% | 25.50% | 16.54% | 12.78% |
Effective Tax Rate | - | - | - | 18.29% | 17.74% | 17.14% |
Revenue as Reported | 1,524 | 1,742 | 1,674 | 4,199 | 1,778 | 1,238 |
Advertising Expenses | - | 0.79 | 0.9 | 3.2 | 3.39 | 0.66 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.